- Home
- TKC vs MIRM Comparison
TKC vs MIRM Comparison
Compare TKC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKC | MIRM |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.7B |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TKC | MIRM |
|---|---|---|
| Price | $5.98 | $99.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.6M | 632.8K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $31.20 | $26.22 |
| Revenue Next Year | $24.27 | $22.04 |
| P/E Ratio | $26.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $47.89 |
| 52 Week High | $7.18 | $114.99 |
Technical Indicators
Market Signals| Indicator | TKC | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 53.73 |
| Support Level | $5.89 | $95.68 |
| Resistance Level | $6.11 | $107.51 |
| Average True Range (ATR) | 0.11 | 4.25 |
| MACD | 0.03 | 0.20 |
| Stochastic Oscillator | 90.91 | 77.87 |
Price Performance
Historical ComparisonAbout TKC Turkcell Iletisim Hizmetleri AS
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.